WAVE Life Sciences Revenue 2014-2021 | WVE

WAVE Life Sciences revenue from 2014 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
WAVE Life Sciences Annual Revenue
(Millions of US $)
2020 $20
2019 $16
2018 $14
2017 $4
2016 $1
2015 $0
2014 $
2013 $
WAVE Life Sciences Quarterly Revenue
(Millions of US $)
2021-06-30 $3
2021-03-31
2020-12-31 $9
2020-09-30 $3
2020-06-30 $3
2020-03-31 $4
2019-12-31 $2
2019-09-30 $3
2019-06-30 $8
2019-03-31 $3
2018-12-31 $4
2018-09-30 $4
2018-06-30 $5
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31
2015-12-31 $0
2015-09-30
2015-06-30 $0
2015-03-31 $0
2014-12-31
2014-09-30
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.314B $0.020B
WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29